Ann: Alterity to Present New Data at the AAN 2024 Annual Meeting, page-3

Hi Iron Pig,

Let me start by just saying what a terrific announcement. Without sounding like someone trying to "pump the SP" let us read between the lines.

Being accepted to present at the Academy of Neurology AAN 2024 (3 Speakers)

Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver,
Colorado, USA.


“We are thrilled to be presenting at this prestigious international neurology conference, including
new baseline biomarker data on ATH434 from our ongoing Phase 2 randomized, double blind
clinical trial in multiple system atrophy (MSA), as well as compelling preclinical primate data on
ATH434 in Parkinson’s disease,” said, David Stamler, M.D., Chief Executive Officer of Alterity. “In
addition, we remain in the vanguard of biomarker evaluation of MSA, as our partners at
Vanderbilt University will present important data from our bioMUSE natural history study. AAN
promises to be a very productive conference for us as we advance our MSA program toward data
later this year and expand our development toward Parkinson’s disease.”

You have to ask yourself, why would you presenting at such a worldwide prestigious event if you had nothing new or exciting to reveal? To me that paragraph above speaks absolute volumes. My hunch would be by the time the event rolls around, we would've released some positive data to the market on the trials. Dr Stamler did mention in previous presentations that news from the "Open Label Study" would start rolling in from March onwards.

Something else that got me excited was the 3 Team Members Presenting at different segments of the conference. I know Prof. Claassen is directly employed by Alterity, but he certainly is still one of the Team! Alterity is certainly covering all bases here. We are leaving no stones unturned...

Title: A Phase 2 Study of ATH434, a Novel Inhibitor of α-Synuclein Aggregation, for the
Treatment of Multiple System Atrophy (MSA)
Lead Author: David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics
Date/Time: Sunday, April 14, from 11:45 a.m. 12:45 p.m. Mountain Time (U.S.)
Title: Neurofilament Light Chain and Clinical Progression in Early Multiple System
Atrophy
Lead Author: Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University
Medical Center
Date/Time: Monday, April 15, from 5:30 p.m. to 6:30 p.m. Mountain Time (U.S.)
Title: Effects of ATH434, a Clinical-phase Small Molecule with Moderate Affinity for
Iron, in a Parkinson's Disease Model in Macaques
Lead Author: Margaret Bradbury, Vice President, Research and Nonclinical Development,
Alterity Therapeutics
Date/Time: Tuesday, April 16, from 11:45 a.m. to 12:45 p.m. Mountain Time (U.S.)

The rest of the announcement remains the same as the previous ones. It just goes over the "Double Blind Study" and the bioMUSE "Open Label".

All in all I think this announcement was very positive and we are certainly heading in the right direction. I am certainly looking forward to seeing some of the results from the bioMUSE study shortly.

GLTAH

Stockman